Melanotan Side Effects: What Studies Report

What "melanotan" refers to in the published record

Two different compounds share the name. Melanotan I is the linear alpha-melanocyte-stimulating hormone (alpha-MSH) analogue afamelanotide, which reached regulated medicine status as a controlled-release subcutaneous implant for erythropoietic protoporphyria, placed by trained health professionals. Melanotan II is a cyclic melanocortin analogue that was studied in small early trials and never became an approved medicine in any major jurisdiction; it circulates as an unregulated injectable powder. A review of unregulated alpha-MSH analogue use reported that products sold outside medical supervision were associated with a range of dermatological and systemic adverse effects and with uncertain composition (PMID 28266027). A Dutch clinical overview of the risks of tanning with the so-called "Barbie drug" similarly described harms reported in users of these injectable tanning peptides (PMID 35736369). This distinction matters when reading adverse-event literature, because most published harm reports concern unsupervised melanotan II rather than the regulated implant.

Melanotan Side Effects: What Studies Report

Gastrointestinal and vasomotor effects

Nausea and facial flushing appear consistently in the descriptive literature. The review of unregulated alpha-MSH analogue use reported nausea, flushing, gastrointestinal upset and dizziness among the effects attributed to melanocortin analogue injections in non-medical settings (PMID 28266027). In the earlier clinical study of a melanocortin analogue in men with organic erectile dysfunction, researchers reported nausea and yawning or stretching as dose-associated effects observed during supervised administration (PMID 11018622).

Skin, moles and pigmented lesions

Because these peptides act on melanocortin receptors on melanocytes, the reported dermatological signals concern pigmentation itself. The review of unregulated use reported generalised darkening of the skin, new or darkening melanocytic naevi, and published cases of melanoma diagnosed in people who had used alpha-MSH analogues, while noting that causation could not be established from case material alone (PMID 28266027). The Dutch clinical overview also framed pigmented-lesion change as the principal dermatological concern raised by injectable tanning agents (PMID 35736369). In a controlled trial setting, researchers reported that a superpotent melanotropic peptide combined with solar ultraviolet radiation increased tanning of the skin in human volunteers more than ultraviolet exposure alone (PMID 15262693) — the same pharmacology that drives the unwanted pigment changes described in the review literature.

Inflammatory and ulcerative skin reactions in case reports

Single-patient reports document reactions beyond pigmentation. A 2025 case report described pyoderma gangrenosum, a painful ulcerating neutrophilic dermatosis, occurring secondary to melanotan use (PMID 41487785). Case reports establish temporal association rather than incidence, and the authors presented it as an individual case rather than a rate.

Sexual function: endpoint in one study, unwanted effect in reviews

The melanocortin system influences sexual response, which is why the same effect appears as a therapeutic endpoint in one literature and as a side effect in another. In the clinical study of men with organic erectile dysfunction, researchers administered an alpha-MSH analogue subcutaneously and reported increased erectile activity and increased subjective sexual desire compared with placebo (PMID 11018622). The review of unregulated use reported spontaneous, unwanted penile erections among effects described by people injecting these analogues for cosmetic tanning purposes (PMID 28266027).

Appetite and body-weight signalling (preclinical)

Melanocortin signalling also sits in the pathway that regulates food intake. In a zebrafish model, the study reported that depletion of alpha-melanocyte-stimulating hormone induced insatiable appetite and gains in energy reserves and body weight (PMID 34440144). That is an animal loss-of-signal experiment, not a human study of an analogue, and the reduced-appetite reports that circulate anecdotally about melanotan II are not established by this work.

Product Identity and Contamination: What Studies Report

A recurring theme in the safety literature is that the substance in an unregulated vial is not necessarily the substance on the label. A 2024 forensic science paper on "Barbie drug" identification reported that analytical characterisation of seized melanotan-type products was technically demanding and that identification of these peptides was not straightforward (PMID 39302005). A broader analytical review of falsification of biotechnology drugs reported that falsified peptide and protein products present current dangers, including wrong identity, wrong content and compromised quality (PMID 30165334). The review of unregulated alpha-MSH analogue use made the same point from the clinical side, reporting that composition, sterility and purity of non-prescription products were unverified (PMID 28266027). This is why adverse events described in users cannot always be attributed to the named peptide.

Timing questions the literature answers — and the ones it does not

Pigmentation onset in melanotan I trials

The human volunteer trial of a superpotent melanotropic peptide measured tanning after a course of subcutaneous administration given together with solar ultraviolet radiation, and researchers reported greater skin pigmentation with the combination than with ultraviolet exposure alone (PMID 15262693). Pigment change in that design was an end-of-course observation, not an immediate response, and no single "hours to effect" figure appears in the verified literature summarised here. The Dutch overview discussed tanning outcomes in descriptive rather than time-stamped terms (PMID 35736369).

Erectile response timing in the melanocortin analogue study

In men with organic erectile dysfunction, the study used monitored sessions after a single subcutaneous injection and researchers reported erectile responses and increased sexual desire during those observation periods rather than after weeks of repeated administration (PMID 11018622). That was a small, supervised investigation of an analogue that did not become an approved therapy, and it does not describe outcomes of non-prescription use.

How long melanotan stays in the system

Among the papers verified for this page, none report a human elimination half-life, urinary detection window or clearance curve for melanotan I or melanotan II. The forensic paper addressed identification of the substance in seized products rather than human pharmacokinetics (PMID 39302005). Visible pigmentation is a separate matter from peptide clearance: the review of unregulated use reported persistent skin darkening and naevus changes as dermatological findings, without linking them to a drug-elimination timeline (PMID 28266027).

Storage, reconstitution and "dose calculator" questions

Refrigeration and post-reconstitution shelf life

No stability, refrigeration or in-use shelf-life data for reconstituted melanotan preparations appear in the verified literature. As a regulatory matter, storage conditions and in-use periods are defined in approved product labelling for licensed medicines and are established by the manufacturer's own stability testing; unlicensed research-use-only powders carry no such validated labelling. Formulation science illustrates why those parameters cannot be assumed: a review of depot-based delivery systems described how formulation and excipient design govern release behaviour and stability of an injectable product (PMID 21696355). Where the contents themselves are uncertain — as the falsification review reported for biotechnology products (PMID 30165334) — stability questions cannot be answered at all.

Mixing and reconstitution of vials

The peer-reviewed record for melanotan contains no reconstitution procedures, diluent volumes or mixing protocols for consumer vials, and this page does not supply any. What the literature does document is the upstream problem: the forensic study reported that identifying these peptides in seized material required specialist analysis (PMID 39302005), and the review of unregulated use reported that sterility and purity of such products were not assured (PMID 28266027). Preparation questions therefore sit outside, not inside, the published evidence base. Regulated melanocortin therapy in dermatology is delivered as a controlled-release implant placed by a clinician, which involves no user preparation at all.

Dose calculators

No validated dose calculator for melanotan exists in this literature. Clinical investigation used weight-based dosing under supervision and with monitoring — for example, researchers in the erectile dysfunction study administered the alpha-MSH analogue subcutaneously on a milligram-per-kilogram basis in a controlled setting (PMID 11018622) — and the tanning trial likewise combined supervised peptide administration with measured ultraviolet exposure (PMID 15262693). Neither design translates into an arithmetic tool for unlabelled powder of unverified content, a limitation the falsification review emphasised for peptide products generally (PMID 30165334).

Where information circulates: What Studies Report

Two papers speak to the information environment around cosmetic skin practices. A study of patient dialogue on rosacea web-based platforms reported that peer-to-peer online discussion carried potential for significant harm through inaccurate or unsafe suggestions (PMID 29676186). A 2025 prospective qualitative analysis of sunbed use among patients attending a pigmented lesion clinic reported gaps between knowledge, attitudes and behaviour in people pursuing tanning despite skin-cancer risk awareness (PMID 40584950). Both contextualise why the melanotan safety literature repeatedly emphasises unverified products and unsupervised practice (PMID 35736369).

Limits of the evidence

• Small and old clinical datasets. The supervised human studies cited here were limited in size and scope, with pigmentation and erectile endpoints assessed under monitoring (PMID 15262693, PMID 11018622).
• Harm data are largely descriptive. Reviews and case reports describe events without denominators, so incidence rates are not established (PMID 28266027, PMID 41487785).
• Exposure is unverified. Analytical work reported identification difficulties and falsification risk, so the injected substance in user reports may differ from the label (PMID 39302005, PMID 30165334).
• Cross-species inference. Appetite and energy findings came from a zebrafish depletion model, not from human analogue administration (PMID 34440144).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, symptom or medication. It summarises what published studies and case reports have described and does not recommend, endorse or instruct any use of melanotan I or melanotan II.

References

• Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review (International Journal of Dermatology, 2017)
• [The risks of tanning with the Barbie drug] (Nederlands Tijdschrift voor Geneeskunde, 2022)
• Barbie drug identification: Not a child's play (Journal of Forensic Sciences, 2024)
• Pyoderma Gangrenosum Secondary to Melanotan (Cureus, 2025)
• Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers (Archives of Dermatology, 2004)
• Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction (Urology, 2000)
• Falsification of biotechnology drugs: current dangers and/or future disasters? (Journal of Pharmaceutical and Biomedical Analysis, 2018)
• Depletion of Alpha-Melanocyte-Stimulating Hormone Induces Insatiable Appetite and Gains in Energy Reserves and Body Weight in Zebrafish (Biomedicines, 2021)
• Depot based drug delivery system for the management of depression (Current Drug Delivery, 2011)
• It takes one to know one: exploring patient dialogue on rosacea web-based platforms and their potential for significant harm (Journal of Dermatological Treatment, 2019)
• A single-centre, prospective, qualitative analysis of knowledge, attitudes and behaviour of sunbed use among patients attending a pigmented lesion clinic in a tertiary referral centre (Skin Health and Disease, 2025)